Business Standard

Can't call Remdesiver, Favipiravir game changers in Covid-19 fight: Experts

Glenmark Pharmaceuticals has launched the antiviral drug Favipiravir, while Cipla and Hetero have received approvals from the Drug Controller General of India to launch Remdesivir

Telemedicine
Premium

Cipla Ltd on Sunday announced the launch of Cipremi

Press Trust of India
With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for Covid-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".

Glenmark Pharmaceuticals has launched the antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of mild to moderate Covid-19 cases, while Cipla and Hetero have received approvals from the Drug Controller General of India (DCGI) to launch Remdesivir under the brand names Cipremi and Covifor respectively.

Cipla Ltd on Sunday announced the launch of Cipremi.

Dr Sanjay Rai, Professor

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in